Ordering Recommendation

May be useful in the comprehensive evaluation of patients with autoimmune neuropathies. Test by itself is not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

Mnemonic
GM1 COMBI
Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Performed

Mon, Wed, Fri

Reported

1-4 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum separator tube.

Specimen Preparation

Separate serum from cells ASAP. Transfer 0.3 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Room temperature specimens. Plasma, CSF, or other body fluids. Contaminated, heat-inactivated, hemolyzed , severely icteric, or lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: Unacceptable; Refrigerated: 2 weeks; Frozen: 1 year

Reference Interval
Test Number
Components
Reference Interval
  Asialo-GM1 Antibodies, IgG/IgM
29 IV or less Negative
30-50 IV Equivocal
51-100 IV Positive
101 IV or greater Strong Positive

  GM1 Antibodies, IgG/IgM
29 IV or less Negative
30-50 IV Equivocal
51-100 IV Positive
101 IV or greater Strong Positive

  GM2 Antibodies, IgG/IgM
29 IV or less Negative
30-50 IV Equivocal
51-100 IV Positive
101 IV or greater Strong Positive

  GD1a Antibodies, IgG/IgM
29 IV or less Negative
30-50 IV Equivocal
51-100 IV Positive
101 IV or greater Strong Positive

  GD1b Antibodies, IgG/IgM
29 IV or less Negative
30-50 IV Equivocal
51-100 IV Positive
101 IV or greater Strong Positive

  GQ1b Antibodies, IgG/IgM
29 IV or less Negative
30-50 IV Equivocal
51-100 IV Positive
101 IV or greater Strong Positive

Interpretive Data

Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1) and the neutral glycolipid, asialo-GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80% of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History
N/A
CPT Codes

83516 x6

Components
Component Test Code* Component Chart Name LOINC
0051034 Asialo-GM1 Antibodies, IgG/IgM 88723-2
0051035 GM1 Antibodies, IgG/IgM 31500-2
0051036 GM2 Antibodies, IgG/IgM 88731-5
0051037 GD1a Antibodies, IgG/IgM 88724-0
0051038 GD1b Antibodies, IgG/IgM 88730-7
0051039 GQ1b Antibodies, IgG/IgM 88729-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Anti-GM Antibodies
  • Asialo-GM1 Antibodies, IgG/IgM
  • Asialo-GM1, GM1, GD1b, GQ1b IgG and IgM
  • Ganglioside Antibodies
  • Ganglioside Abs IgG and IgM
  • GM1, GM2, GD1a, GD1b, GQ1b IgG/IgM
Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies